Report overview
This report contains market size and forecasts of Next-Generation Gynecological Cancer Diagnostics in Global, including the following market information:
Global Next-Generation Gynecological Cancer Diagnostics Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Next-Generation Gynecological Cancer Diagnostics market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Ovarian Cancer Diagnosis Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Next-Generation Gynecological Cancer Diagnostics include Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Invitae Corporation, Konica Minolta, Inc., BGI Genomics, CENTOGENE N.V., Fulgent Genetics, Inc. and Illumina, Inc., etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Next-Generation Gynecological Cancer Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Next-Generation Gynecological Cancer Diagnostics Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global Next-Generation Gynecological Cancer Diagnostics Market Segment Percentages, by Type, 2022 (%)
Ovarian Cancer Diagnosis
Cervical Cancer Diagnosis
Uterine Cancer Diagnosis
Global Next-Generation Gynecological Cancer Diagnostics Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Next-Generation Gynecological Cancer Diagnostics Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global Next-Generation Gynecological Cancer Diagnostics Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Next-Generation Gynecological Cancer Diagnostics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Next-Generation Gynecological Cancer Diagnostics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Next-Generation Gynecological Cancer Diagnostics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Quest Diagnostics Incorporated
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
Invitae Corporation
Konica Minolta, Inc.
BGI Genomics
CENTOGENE N.V.
Fulgent Genetics, Inc.
Illumina, Inc.
F. Hoffmann-La Roche Ltd
Laboratory Corporation of America Holdings
ARUP Laboratories
Myriad Genetics, Inc.
OPKO Health, Inc.
QIAGEN N.V.
